X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1400) 1400
Publication (88) 88
Book Review (24) 24
Newsletter (14) 14
Magazine Article (8) 8
Newspaper Article (7) 7
Book Chapter (4) 4
Conference Proceeding (2) 2
Transcript (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tadalafil (1295) 1295
humans (1024) 1024
male (961) 961
index medicus (754) 754
erectile dysfunction (557) 557
erectile dysfunction - drug therapy (551) 551
carbolines - therapeutic use (522) 522
sildenafil (495) 495
middle aged (461) 461
sildenafil citrate (425) 425
urology & nephrology (421) 421
phosphodiesterase inhibitors - therapeutic use (366) 366
treatment outcome (344) 344
impotence (317) 317
phosphodiesterase 5 inhibitors - therapeutic use (315) 315
adult (314) 314
aged (288) 288
vardenafil (257) 257
men (251) 251
piperazines - therapeutic use (234) 234
pharmacology & pharmacy (231) 231
double-blind (220) 220
vardenafil dihydrochloride (212) 212
efficacy (207) 207
animals (200) 200
female (176) 176
sulfones - therapeutic use (175) 175
analysis (160) 160
double-blind method (159) 159
drug therapy (156) 156
safety (155) 155
care and treatment (153) 153
carbolines - adverse effects (151) 151
imidazoles - therapeutic use (142) 142
carbolines - administration & dosage (141) 141
hypertension, pulmonary - drug therapy (135) 135
carbolines - pharmacology (133) 133
purines - therapeutic use (131) 131
phosphodiesterase inhibitors - adverse effects (121) 121
pulmonary hypertension (119) 119
erectile dysfunction - etiology (118) 118
vasodilator agents - therapeutic use (117) 117
tadalafil - therapeutic use (115) 115
triazines - therapeutic use (115) 115
benign prostatic hyperplasia (113) 113
therapy (111) 111
dosage and administration (108) 108
purines (106) 106
drug therapy, combination (102) 102
hypertension (102) 102
nitric-oxide (101) 101
phosphodiesterase 5 inhibitors (99) 99
phosphodiesterase 5 inhibitors - administration & dosage (97) 97
phosphodiesterase 5 inhibitors - pharmacology (97) 97
cyclic nucleotide phosphodiesterases, type 5 (95) 95
penile erection - drug effects (95) 95
rats (95) 95
patient satisfaction (92) 92
phosphodiesterase inhibitors - administration & dosage (90) 90
phosphodiesterase inhibitors - pharmacology (90) 90
research (90) 90
surveys and questionnaires (90) 90
sexual disorders (89) 89
risk factors (87) 87
dose-response relationship, drug (86) 86
urology (86) 86
phosphodiesterase 5 inhibitors - adverse effects (84) 84
medicine & public health (81) 81
clinical trials (78) 78
prostate (78) 78
time factors (77) 77
prostatic hyperplasia - drug therapy (75) 75
erectile dysfunction - physiopathology (74) 74
health aspects (73) 73
inhibitors (72) 72
young adult (72) 72
cardiac & cardiovascular systems (70) 70
international index (70) 70
prospective studies (70) 70
sulfones (70) 70
drug administration schedule (69) 69
lower urinary tract symptoms (68) 68
medicine, general & internal (68) 68
pde5 inhibitors (68) 68
pulmonary arterial hypertension (68) 68
sexual dysfunction (68) 68
nitric oxide (67) 67
chemistry, analytical (66) 66
phosphodiesterase type 5 inhibitors (66) 66
prostatic hyperplasia - complications (66) 66
piperazines - adverse effects (65) 65
randomized controlled trials as topic (65) 65
administration, oral (64) 64
phosphodiesterase inhibitors (64) 64
piperazines - pharmacology (63) 63
prevalence (62) 62
complications and side effects (61) 61
hypertrophy (61) 61
quality-of-life (60) 60
placebo-controlled trial (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1313) 1313
Chinese (46) 46
German (24) 24
Russian (13) 13
French (10) 10
Spanish (8) 8
Japanese (6) 6
Italian (4) 4
Hungarian (2) 2
Polish (2) 2
Czech (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
Journal Article
Wilderness & Environmental Medicine, ISSN 1080-6032, 2010, Volume 21, Issue 2, pp. 146 - 155
Journal Article
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 8, pp. 1049 - 1066
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 12/2011, Volume 8, Issue 12, pp. 3418 - 3432
Erectile dysfunction (ED) is a very common multidimensional disorder affecting men worldwide. Physical illness, reaction to life stresses, or an unhappy couple... 
Erectile Dysfunction | PDE5 Inhibitors | Tailored Treatment | PDE5 inhibitors | Tailored treatment | Erectile dysfunction | TESTOSTERONE GEL | SILDENAFIL CITRATE | PENILE REHABILITATION | SEMEN CHARACTERISTICS | DEPRESSIVE SYMPTOMS | TADALAFIL PHARMACOKINETICS | URINARY-TRACT SYMPTOMS | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | SEXUAL DYSFUNCTION | HYPOGONADAL MEN | Impotence, Vasculogenic - drug therapy | Sulfones - therapeutic use | Impotence, Vasculogenic - etiology | Impotence, Vasculogenic - pathology | Triazines - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Hypertension - drug therapy | Male | Sulfones - pharmacology | Sildenafil Citrate | Men's Health | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Imidazoles - therapeutic use | Phosphodiesterase 5 Inhibitors - pharmacology | Carbolines - therapeutic use | Cardiovascular Diseases - physiopathology | Triazines - pharmacology | Purines - pharmacology | Risk Factors | Diabetes Mellitus - drug therapy | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Piperazines - pharmacology | Hypertension - physiopathology | Tadalafil | Algorithms | Sulfonamides - therapeutic use | Diabetes Mellitus - physiopathology | Pyrimidines - therapeutic use | Vardenafil Dihydrochloride | Carbolines - pharmacology | Usage | Sildenafil | Impotence
Journal Article